# Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma

> **NCT01804374** · PHASE2 · COMPLETED · sponsor: **Italian Sarcoma Group** · enrollment: 38 (actual)

## Conditions studied

- Metastatic Osteosarcoma
- Relapsed Osteosarcoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01804374
- **Lead sponsor:** Italian Sarcoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804374, "Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01804374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*